Quadruple Misfolded Proteins in Older Adults

- Posted by admin in English

In this cohort study, Shama Karanth and colleagues from University of Kentucky, Lexington, investigated quadruple misfolded proteins and other proteinopathy combinations in a cohort of 375 deceased individuals with autopsy data in the University of Kentucky Alzheimer Disease Center (UK-ADC).

At least 3 proteinopathies were observed in 50% of brains.

In addition, quadruple misfolded proteins were associated with severe cognitive impairment at least 12 years before death.

Participants with 3 proteinopathies tended to have poorer global cognition earlier than with the presence of only tau and Aβ and were likely to have higher Braak stages.

Previous studies have reported cognitive decline associated with the presence of mixed pathologies, with study to study differences in methods and proteinopathies, the assessment and inclusion of cerebrovascular pathologies, and hippocampal sclerosis. In the present sample, as in other community based cohorts, FTLD in old age was rare (with an estimated incidence of 8.9 of 100 000 in individuals aged 60 to 69 years; no incidence data are available for older age groups) and was not found in brains of individuals who began follow up with normal cognition.

Individuals with FTLD-TDP-43 with data in the UK-ADC Brain Bank were recruited from a dementia clinic. The scientists excluded 6 individuals with FTLD-TDP-43 in the study; none had the quadruple misfolded proteins phenotype. No discernible overlap in any FTLD feature was observed in these individuals other than presence of TDP-43 proteinopathy, which is now detected in many different neurological diseases outside of the amyotrophic lateral sclerosis–FTLD spectrum.

Cognitive impairment was associated with quadruple misfolded proteins at autopsy, with 89.1% of participants developing dementia and some experiencing profound impairment up to 12 years before death. This finding suggests that quadruple misfolded proteins occur before end stage Alzheimer disease neuropathological change (ie, before high Braak stage).

Consistent with this hypothesis, the mild cognitive impairment to dementia transition was, on average, fastest in the quadruple misfolded proteins group. Estimation of the group cognitive trajectories was aided by the relatively long followup (mean duration of 10.4 years).

These data provide the basis for a novel hypothesis that quadruple misfolded proteins have a more aggressive phenotype from the early stages of the disease rather than accruing additional pathologies only after Alzheimer disease neuropathological change has progressed to high levels. About 10% of these participants died with normal cognition, and previous research has shown quadruple misfolded proteins were present in persons with apparently normal cognition. In the present study, all individuals with quadruple misfolded proteins who had normal cognition at the last visit before death had lower Braak NFT stages (I to III), had no APOEε4 allele, and were predominantly male (4 of 5 participants).

These individuals may represent an early stage of quadruple misfolded proteins, but there are complexities: clinical presentation of proteinopathy combinations may be cohort specific and depend on other currently unknown factors. Older cohorts that survive into advanced old age, like those in the UK-ADC study, may be more likely to experience multiple proteinopathies than younger cohorts. As previously described, APOE appeared to be associated with multiple proteinopathies in this study, particularly those proteinopathy combinations including Aβ plaques. Carriers of APOEε allele not only had increased odds of tau and Aβ, an expected result, but also had higher odds of tau, Aβ, and αsynuclein; tau, Aβ, and TDP-43; and quadruple misfolded proteins.

Unlike previous studies, this study did not find evidence that the ε4 allele was associated with tau or TDP-43 in the absence of Aβ, but the sample size was relatively small. The temporality of protein misfolding may play a clinically important and differentiating role in disease progression.

Autopsy data, although cross-sectional by nature, are compatible with the hypothesis that Aβ aggregates precede, and perhaps stimulate or exacerbate, the widespread misfolding of tau, TDP-43, and α-synuclein. These results suggest that TDP-43 pathology may be associated with poor global cognition.

The presence of multiple proteinopathies, particularly the quadruple misfolded proteins phenotype, appeared to have been associated with the cognitive decline in deceased individuals who participated in a longitudinal community based study at the UK-ADC.

These observations have potentially significant implications for clinical practice and public health, given that strategies to prevent or manage AD dementia may be complicated by the unrecognized presence of multiple additional neuropathologies.

Two epigenetic regulators interfere with healthy aging

- Posted by admin in English

It has long been assumed that lifespan and health are strongly correlated, but although there has been an overall increase in human life expectancy in recent decades, it is too often accompanied by deterioration of health.

A new study published on February 26 in Nature shows the influence of two epigenetic regulators on aging. Scientists led by Jie Yuan from the Chinese Academy of Sciences in Shanghai have studied the BAZ-2 and SET-6 proteins in Caenorhabditis elegans worms, which are orthologs of the human proteins BAZ2B and EHMT1.

Through genome-wide RNA-interference-based screening of genes that regulate behavioral deterioration in aging C. elegans, the researchers identified 59 genes as potential health modulators during aging. Essentially the proteins expressed by these genes, read and write epigenetic signals.

Among these modulators, they found that a neuronal epigenetic reader, BAZ-2, and a neuronal histone SET-6, accelerate the deterioration of the behavior of C. elegans by reducing the mitochondrial function, and repressing the expression of the encoded mitochondrial proteins. in the cell nucleus.

The researchers found that the levels of the two proteins increase with age in C. elegans and mice, which in turn attenuates the expression of genes involved in mitochondrial function.

BAZ-2 and SET-6 are complementary epigenetic mechanisms. SET-6 is an "epigenetic writer" and BAZ-2 is an "epigenetic reader" which recognizes modified histones and recruits transcriptional regulators.

Histones are proteins located in the nucleus of eukaryotic cells. They are the main protein components of chromosomes. They are closely associated with DNA and allow their compaction, but they also modify the expression of proteins by various epigenetic mechanisms known as the "histone code".

enter image description here Source Wikipedia.

How do BAZ-2 and SET-6 accelerate aging? The researchers found that the two proteins bind together to the promoter regions of more than 2,000 genes, and decrease their expression via methylation of histones. Among these target genes are many mitochondrial genes encoded nuclear. By suppressing the expression of these genes, BAZ-2 and SET-6 reduce oxygen consumption and ATP production, and decrease the critical stress responses that maintain mitochondrial proteostasis. The resulting metabolic slowdown discourages the worms from assimilating their food and they mate less.

This mechanism is conserved in the neurons of cultured mice and human cells. What about the orthologs of these epigenetic proteins in humans? A review of the databases shows that expression by human orthologs of the two proteins mentioned above, BAZ2B and EHMT1, increases with age and is positively correlated with the progression of Alzheimer's disease. Researchers have verified that ablation of BAZ-2 mouse ortholog Baz2b attenuates age-dependent body weight gain and prevents cognitive decline in aging mice.

enter image description here While wild-type mice grew fat with age, animals lacking both copies of the epigenetic reader Baz2b stayed trim, indicating improved mitochondrial function. [Yuan et al., Nature, 2020.]

However, it must be asked whether BAZ-2 and SET-6 would rather mediate age-related physiological adaptation, rather than the agents of aging itself. Indeed their action could reflect a mechanism of adaptation to a progressively more hostile biological environment.

Old Article 5

- Posted by system in English

Old Article 4

- Posted by system in English

Old Article 3

- Posted by system in English

Old Article 2

- Posted by system in English

Old Article 1

- Posted by system in English

Feedforward control is impaired after stroke, but whether practice improves it in the chronic stage remains unclear. In fast single-joint movements, feedforward control scales initial acceleration to movement amplitude. Feedback-error-learning theory predicts that fast practice should promote recalibration. We tested whether speed-emphasized reach training improved this scaling in the more-affected arm. Thirty-six individuals with mild-to-moderate chronic stroke completed 2,080 reaches over four sessions emphasizing Speed (n = 17) or Accuracy (n = 19). At baseline, 3 days, and 1 month after training, participants performed single-joint elbow movements of three amplitudes without online visual feedback. The slope relating initial peak acceleration to target amplitude quantified feedforward scaling. At baseline, scaling was reduced on the more-affected side for extension ({Delta}{beta} = -17.1 {+/-} 3.5 s-{superscript 2}, P < 0.001) and flexion ({Delta}{beta} = -21.9 {+/-} 3.2 s-{superscript 2}, P < 0.001). Speed training increased flexion scaling at 3 days ({Delta}{beta} = 14.7 {+/-} 3.6 s-{superscript 2}, P = 0.00029), with 14 of 17 participants improving. The group-by-session interaction showed a greater increase after Speed than Accuracy training ({Delta}{beta} = 14.13 {+/-} 4.9 s-{superscript 2}, P = 0.0053). Scaling declined by 1 month (P = 0.02); no training-related changes occurred for extension. Peak acceleration occurred within 100 ms. Time to peak velocity, an index of pulse width, showed no group-specific training effect. Thus, speed-emphasized training produced a short-term improvement in early flexion acceleration scaling that transferred to an untrained single-joint task and was consistent with improved feedforward control. Transfer primarily reflected acceleration pulse-height rather than pulse-width modulation.

Read the original article on medRxiv

Significance of the Topic

The topic of this text revolves around understanding the molecular mechanisms underlying the genetic risks associated with Alzheimer's disease (Alzheimer's disease) conferred by the Apolipoprotein E (APOE) gene. Specifically, it explores the role of the 4 and 2 alleles of the APOE gene in modulating Alzheimer's disease pathology. The significance of this topic lies in its potential to shed light on the underlying biology of Alzheimer's disease, a complex and multifactorial disease.

Importance

Alzheimer's disease is a devastating and debilitating neurodegenerative disorder that affects millions of people worldwide. Understanding the genetic and molecular mechanisms underlying Alzheimer's disease is crucial for developing effective therapeutic strategies and preventing or slowing disease progression. The APOE gene has been associated with Alzheimer's disease risk, with the 4 allele being a well-established risk factor.

However, the underlying molecular mechanisms remain poorly characterized, making this research area highly important and timely.

Timeliness

The text is timely as it addresses a critical knowledge gap in the field of Alzheimer's disease research. Recent advances in proteomics and genomics have enabled researchers to systematically profile APOE-associated proteomic alterations in human samples, providing new insights into the molecular mechanisms underlying Alzheimer's disease. The text leverages these advances to investigate the role of the APOE 4 and 2 alleles in Alzheimer's disease pathology, making it a timely contribution to the field.

Relevance

The text has significant relevance to Alzheimer's disease research, as it provides novel insights into the molecular mechanisms underlying APOE-driven Alzheimer's disease pathology. The findings have implications for the development of therapeutic strategies for early intervention and potentially for the identification of new targets for Alzheimer's disease treatment.

Furthermore, the text highlights the importance of considering the APOE 4 and 2 alleles as distinct risk factors for Alzheimer's disease, rather than just focusing on the 4 allele.

Analysis of the Text

The text presents a comprehensive analysis of APOE-associated proteomic alterations across five cohorts, using a range of proteomics platforms and samples, including plasma and cerebrospinal fluid (cerebrospinal fluid). The study uses systematic profiling to identify a comprehensive APOE-protein network and applies mediation modeling to classify genotype-related signals as upstream mediators, downstream consequences, or APOE-specific changes. The text then leverages cerebrospinal fluid beta-amyloid (A ) biomarker data to improve temporal resolution and isolate early, A -independent proteomic programs.

The findings of the text are significant, as they provide novel insights into the molecular mechanisms underlying APOE-driven Alzheimer's disease pathology. The study identifies allele-specific, temporally structured proteomic signatures that precede Alzheimer's disease pathology, offering potential therapeutic targets for early intervention. The text highlights the importance of considering the APOE 4 and 2 alleles as distinct risk factors for Alzheimer's disease and underscores the challenges in reproducibility associated with proteomics studies.

Usefulness for Disease Management and Drug Discovery

The text provides valuable insights for Alzheimer's disease disease management and drug discovery, as it highlights the potential therapeutic targets for early intervention. The identification of allele-specific, temporally structured proteomic signatures offers a new perspective on Alzheimer's disease pathology and provides a starting point for the development of novel therapeutic strategies. The text also underscores the importance of considering individual variability in APOE genotype as a critical factor in Alzheimer's disease risk, which may inform personalized medicine approaches.

Original Information Beyond the Obvious

While the text presents novel insights into the molecular mechanisms underlying APOE-driven Alzheimer's disease pathology, it does not break new ground in terms of fundamental understanding.

However, the systematic profiling and mediation modeling approaches used in the study provide a comprehensive and nuanced understanding of APOE-associated proteomic alterations, which is a significant advance in the field. The text highlights the challenges associated with reproducibility in proteomics studies, emphasizing the need for careful consideration of sample size, platform choice, and data analysis methods.

Overall, the text provides a comprehensive and insightful analysis of APOE-associated proteomic alterations in human samples, highlighting the importance of considering individual variability in APOE genotype as a critical factor in Alzheimer's disease risk. The findings offer novel insights into the molecular mechanisms underlying APOE-driven Alzheimer's disease pathology and provide potential therapeutic targets for early intervention.

Read the original article on medRxiv

Background: Stroke survivors frequently experience post-stroke depression (PSD) and post-stroke anxiety (PSA), which may be underexamined by clinicians if patient mood status between discharge and follow-up is unknown. Digital monitoring may enable early identification of mood disturbances. Ecological momentary assessments (EMA) have been tested to capture mood fluctuations in patients regular environments, but no standardized procedure for monitoring PSA or PSD has been developed. Objective: Determine the feasibility and validity of EMA for evaluating subacute PSA and PSD in non-severe stroke patients. Methods: Patients with non-severe stroke discharged home responded to daily smartphone EMA questions concerning mood and activity for twelve weeks until follow-up. Questions based on symptoms of anxiety and depression were used to derive EMA Anx and EMA Dep indices, computed over five 15-day intervals. Convergent validity was assessed using follow-up Generalized Anxiety Disorder-7 (GAD-7) and Centre for Epidemiological Studies-Depression (CES-D) scores. Logistic regression models predicted PSA and PSD status at follow-up, with baseline models comprising stroke severity, age, sex, and mood status, to which EMA Anx or Dep were added. Results: Data from 118 patients were analyzed. EMA adherence was moderate, with 89 patients (75.4%) responding on 75 or more days. Correlations between EMA Anx and GAD-7 and between EMA Dep and CES-D generally strengthened at later intervals, with the average mood index generally showing the strongest associations. Adding EMA data from the third time interval (31-45 days) significantly improved model fit beyond the baseline models (Anxiety: {chi}-square = 7.08, p = 0.008, {delta}R-square = 0.060; Depression: {chi}-square = 28.0, p < 0.001, {delta}R-square = 0.256). Discussion: EMA is feasible in mild-to-moderate stroke patients and may facilitate early identification of post-stroke mood disturbances. Further analyses in more diverse populations are required to validate these findings.

Read the original article on medRxiv


Please, help us continue to provide valuable information: